Which has preferable valuation & earnings, TRLV or AGMB?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Trulieve Cannabis $1.17B 1.38 N/A N/A N/A AgomAb Therapeutics N/A N/A N/A N/A N/A

Is TRLV or AGMB more profitable?

Company Net Margins Return on Equity Return on Assets Trulieve Cannabis N/A N/A N/A AgomAb Therapeutics N/A N/A N/A

Does the media prefer TRLV or AGMB?

In the previous week, AgomAb Therapeutics had 2 more articles in the media than Trulieve Cannabis. MarketBeat recorded 5 mentions for AgomAb Therapeutics and 3 mentions for Trulieve Cannabis. AgomAb Therapeutics' average media sentiment score of 0.96 beat Trulieve Cannabis' score of 0.00 indicating that AgomAb Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Trulieve Cannabis 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral AgomAb Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, HROW or AGMB?

AgomAb Therapeutics has lower revenue, but higher earnings than Harrow. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Harrow $268.68M 5.33 -$5.14M -$0.41 N/A AgomAb Therapeutics N/A N/A N/A N/A N/A

Does the media refer more to HROW or AGMB?

In the previous week, Harrow had 5 more articles in the media than AgomAb Therapeutics. MarketBeat recorded 10 mentions for Harrow and 5 mentions for AgomAb Therapeutics. AgomAb Therapeutics' average media sentiment score of 0.96 beat Harrow's score of 0.50 indicating that AgomAb Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Harrow 1 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral AgomAb Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, AGMB or TSHA?

AgomAb Therapeutics has higher earnings, but lower revenue than Taysha Gene Therapies. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AgomAb Therapeutics N/A N/A N/A N/A N/A Taysha Gene Therapies $7.47M 212.32 -$109M -$0.38 N/A

Is AGMB or TSHA more profitable?

AgomAb Therapeutics' return on equity of 0.00% beat Taysha Gene Therapies' return on equity. Company Net Margins Return on Equity Return on Assets AgomAb Therapeutics N/A N/A N/A Taysha Gene Therapies N/A -56.07% -40.16%

Does the media prefer AGMB or TSHA?

In the previous week, AgomAb Therapeutics had 1 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 5 mentions for AgomAb Therapeutics and 4 mentions for Taysha Gene Therapies. Taysha Gene Therapies' average media sentiment score of 1.65 beat AgomAb Therapeutics' score of 0.96 indicating that Taysha Gene Therapies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AgomAb Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Taysha Gene Therapies 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has preferable valuation & earnings, AGMB or CMPS?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AgomAb Therapeutics N/A N/A N/A N/A N/A Compass Pathways N/A N/A -$287.86M -$3.15 N/A

Is AGMB or CMPS more profitable?

AgomAb Therapeutics' return on equity of 0.00% beat Compass Pathways' return on equity. Company Net Margins Return on Equity Return on Assets AgomAb Therapeutics N/A N/A N/A Compass Pathways N/A -31.07% -11.40%

Does the media prefer AGMB or CMPS?

In the previous week, Compass Pathways had 2 more articles in the media than AgomAb Therapeutics. MarketBeat recorded 7 mentions for Compass Pathways and 5 mentions for AgomAb Therapeutics. AgomAb Therapeutics' average media sentiment score of 0.96 beat Compass Pathways' score of 0.84 indicating that AgomAb Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AgomAb Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Compass Pathways 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, AGMB or MAZE?

AgomAb Therapeutics has higher earnings, but lower revenue than Maze Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AgomAb Therapeutics N/A N/A N/A N/A N/A Maze Therapeutics $20M 76.60 -$131.12M -$2.53 N/A

Is AGMB or MAZE more profitable?

AgomAb Therapeutics' return on equity of 0.00% beat Maze Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets AgomAb Therapeutics N/A N/A N/A Maze Therapeutics N/A -36.62% -31.78%

Does the media refer more to AGMB or MAZE?

In the previous week, AgomAb Therapeutics had 1 more articles in the media than Maze Therapeutics. MarketBeat recorded 5 mentions for AgomAb Therapeutics and 4 mentions for Maze Therapeutics. Maze Therapeutics' average media sentiment score of 1.24 beat AgomAb Therapeutics' score of 0.96 indicating that Maze Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AgomAb Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Maze Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

AgomAb Therapeutics (AGMB) Competitors

$12.51 -0.46 (-3.55%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$12.56 +0.05 (+0.44%)

As of 07/24/2026 07:34 PM Eastern

Compare

AGMB vs. TRLV, HROW, TSHA, CMPS, and MAZE

Should you buy AgomAb Therapeutics stock or one of its competitors? MarketBeat compares AgomAb Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with AgomAb Therapeutics include Trulieve Cannabis (TRLV), Harrow (HROW), Taysha Gene Therapies (TSHA), Compass Pathways (CMPS), and Maze Therapeutics (MAZE). These companies are all part of the "pharmaceutical products" industry.

How does AgomAb Therapeutics compare to Trulieve Cannabis?

Trulieve Cannabis (NYSE:TRLV) and AgomAb Therapeutics (NASDAQ:AGMB) are both small-cap manufacturing companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.

Trulieve Cannabis presently has a consensus target price of $15.00, indicating a potential upside of 79.17%. AgomAb Therapeutics has a consensus target price of $33.00, indicating a potential upside of 163.79%. Given AgomAb Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe AgomAb Therapeutics is more favorable than Trulieve Cannabis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trulieve Cannabis	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
AgomAb Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83

Company	Net Margins	Return on Equity	Return on Assets
Trulieve Cannabis	N/A	N/A	N/A
AgomAb Therapeutics	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trulieve Cannabis	$1.17B	1.38	N/A	N/A	N/A
AgomAb Therapeutics	N/A	N/A	N/A	N/A	N/A

In the previous week, AgomAb Therapeutics had 2 more articles in the media than Trulieve Cannabis. MarketBeat recorded 5 mentions for AgomAb Therapeutics and 3 mentions for Trulieve Cannabis. AgomAb Therapeutics' average media sentiment score of 0.96 beat Trulieve Cannabis' score of 0.00 indicating that AgomAb Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Trulieve Cannabis	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
AgomAb Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

AgomAb Therapeutics beats Trulieve Cannabis on 5 of the 6 factors compared between the two stocks.

How does AgomAb Therapeutics compare to Harrow?

Harrow (NASDAQ:HROW) and AgomAb Therapeutics (NASDAQ:AGMB) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends, media sentiment and risk.

AgomAb Therapeutics has lower revenue, but higher earnings than Harrow.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harrow	$268.68M	5.33	-$5.14M	-$0.41	N/A
AgomAb Therapeutics	N/A	N/A	N/A	N/A	N/A

Harrow currently has a consensus target price of $69.43, indicating a potential upside of 80.57%. AgomAb Therapeutics has a consensus target price of $33.00, indicating a potential upside of 163.79%. Given AgomAb Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe AgomAb Therapeutics is more favorable than Harrow.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harrow	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
AgomAb Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83

72.8% of Harrow shares are owned by institutional investors. 12.8% of Harrow shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

AgomAb Therapeutics has a net margin of 0.00% compared to Harrow's net margin of -5.57%. Harrow's return on equity of 19.59% beat AgomAb Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Harrow	-5.57%	19.59%	2.26%
AgomAb Therapeutics	N/A	N/A	N/A

In the previous week, Harrow had 5 more articles in the media than AgomAb Therapeutics. MarketBeat recorded 10 mentions for Harrow and 5 mentions for AgomAb Therapeutics. AgomAb Therapeutics' average media sentiment score of 0.96 beat Harrow's score of 0.50 indicating that AgomAb Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Harrow	1 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
AgomAb Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Harrow beats AgomAb Therapeutics on 7 of the 11 factors compared between the two stocks.

How does AgomAb Therapeutics compare to Taysha Gene Therapies?

AgomAb Therapeutics (NASDAQ:AGMB) and Taysha Gene Therapies (NASDAQ:TSHA) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, media sentiment, risk and dividends.

AgomAb Therapeutics has higher earnings, but lower revenue than Taysha Gene Therapies.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AgomAb Therapeutics	N/A	N/A	N/A	N/A	N/A
Taysha Gene Therapies	$7.47M	212.32	-$109M	-$0.38	N/A

77.7% of Taysha Gene Therapies shares are owned by institutional investors. 3.5% of Taysha Gene Therapies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

AgomAb Therapeutics currently has a consensus price target of $33.00, suggesting a potential upside of 163.79%. Taysha Gene Therapies has a consensus price target of $12.77, suggesting a potential upside of 131.33%. Given AgomAb Therapeutics' higher possible upside, research analysts clearly believe AgomAb Therapeutics is more favorable than Taysha Gene Therapies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AgomAb Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
Taysha Gene Therapies	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	3.00

AgomAb Therapeutics' return on equity of 0.00% beat Taysha Gene Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AgomAb Therapeutics	N/A	N/A	N/A
Taysha Gene Therapies	N/A	-56.07%	-40.16%

In the previous week, AgomAb Therapeutics had 1 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 5 mentions for AgomAb Therapeutics and 4 mentions for Taysha Gene Therapies. Taysha Gene Therapies' average media sentiment score of 1.65 beat AgomAb Therapeutics' score of 0.96 indicating that Taysha Gene Therapies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AgomAb Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Taysha Gene Therapies	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Taysha Gene Therapies beats AgomAb Therapeutics on 7 of the 11 factors compared between the two stocks.

How does AgomAb Therapeutics compare to Compass Pathways?

AgomAb Therapeutics (NASDAQ:AGMB) and Compass Pathways (NASDAQ:CMPS) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, risk, media sentiment and institutional ownership.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AgomAb Therapeutics	N/A	N/A	N/A	N/A	N/A
Compass Pathways	N/A	N/A	-$287.86M	-$3.15	N/A

AgomAb Therapeutics' return on equity of 0.00% beat Compass Pathways' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AgomAb Therapeutics	N/A	N/A	N/A
Compass Pathways	N/A	-31.07%	-11.40%

46.2% of Compass Pathways shares are owned by institutional investors. 2.8% of Compass Pathways shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

AgomAb Therapeutics currently has a consensus price target of $33.00, suggesting a potential upside of 163.79%. Compass Pathways has a consensus price target of $24.15, suggesting a potential upside of 114.51%. Given AgomAb Therapeutics' higher probable upside, equities research analysts plainly believe AgomAb Therapeutics is more favorable than Compass Pathways.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AgomAb Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
Compass Pathways	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.94

In the previous week, Compass Pathways had 2 more articles in the media than AgomAb Therapeutics. MarketBeat recorded 7 mentions for Compass Pathways and 5 mentions for AgomAb Therapeutics. AgomAb Therapeutics' average media sentiment score of 0.96 beat Compass Pathways' score of 0.84 indicating that AgomAb Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AgomAb Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Compass Pathways	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Compass Pathways beats AgomAb Therapeutics on 6 of the 10 factors compared between the two stocks.

How does AgomAb Therapeutics compare to Maze Therapeutics?

AgomAb Therapeutics (NASDAQ:AGMB) and Maze Therapeutics (NASDAQ:MAZE) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, media sentiment, analyst recommendations and profitability.

AgomAb Therapeutics currently has a consensus price target of $33.00, suggesting a potential upside of 163.79%. Maze Therapeutics has a consensus price target of $66.00, suggesting a potential upside of 138.44%. Given AgomAb Therapeutics' higher probable upside, equities research analysts plainly believe AgomAb Therapeutics is more favorable than Maze Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AgomAb Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
Maze Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00

AgomAb Therapeutics' return on equity of 0.00% beat Maze Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AgomAb Therapeutics	N/A	N/A	N/A
Maze Therapeutics	N/A	-36.62%	-31.78%

In the previous week, AgomAb Therapeutics had 1 more articles in the media than Maze Therapeutics. MarketBeat recorded 5 mentions for AgomAb Therapeutics and 4 mentions for Maze Therapeutics. Maze Therapeutics' average media sentiment score of 1.24 beat AgomAb Therapeutics' score of 0.96 indicating that Maze Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AgomAb Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Maze Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

AgomAb Therapeutics has higher earnings, but lower revenue than Maze Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AgomAb Therapeutics	N/A	N/A	N/A	N/A	N/A
Maze Therapeutics	$20M	76.60	-$131.12M	-$2.53	N/A

Summary

Maze Therapeutics beats AgomAb Therapeutics on 5 of the 9 factors compared between the two stocks.

Get AgomAb Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AGMB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AGMB vs. The Competition

Export

Metric	AgomAb Therapeutics	Biological Products, Except Diagnostic Substances Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$453.33M	$640.25M	$7.24B	$12.26B
Dividend Yield	N/A	N/A	40.99%	9.79%
P/E Ratio	N/A	N/A	23.62	23.64
Price / Sales	N/A	60.23	132.14	89.45
Price / Cash	N/A	N/A	165.01	59.64
Price / Book	N/A	2.52	12.77	6.07
Net Income	N/A	-$75.73M	$120.21M	$331.99M
7 Day Performance	3.90%	-1.46%	-0.98%	-0.63%
1 Month Performance	-6.85%	12.75%	-2.00%	-2.00%
1 Year Performance	N/A	-77.48%	9.75%	13.62%

AgomAb Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AGMB AgomAb Therapeutics	N/A	$12.51 -3.5%	$33.00 +163.8%	N/A	$453.33M	N/A	N/A	62	News Coverage Analyst Forecast
TRLV Trulieve Cannabis	2.8962 of 5 stars	$8.84 +0.9%	$15.00 +69.8%	N/A	$1.68B	$1.17B	N/A	9,000	Short Interest Increase
HROW Harrow	4.1395 of 5 stars	$43.71 -1.7%	$69.43 +58.8%	+3.2%	$1.66B	$268.68M	N/A	180	News Coverage Analyst Forecast
TSHA Taysha Gene Therapies	3.1443 of 5 stars	$5.67 +1.6%	$12.77 +125.2%	+113.1%	$1.60B	$7.47M	N/A	180	News Coverage Positive News Analyst Forecast
CMPS Compass Pathways	3.1085 of 5 stars	$12.18 +4.4%	$24.15 +98.3%	+157.7%	$1.57B	N/A	N/A	120	News Coverage Positive News Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AGMB) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AgomAb Therapeutics (AGMB) Competitors

AGMB vs. TRLV, HROW, TSHA, CMPS, and MAZE

How does AgomAb Therapeutics compare to Trulieve Cannabis?

Summary

How does AgomAb Therapeutics compare to Harrow?

Summary

How does AgomAb Therapeutics compare to Taysha Gene Therapies?

Summary

How does AgomAb Therapeutics compare to Compass Pathways?

Summary

How does AgomAb Therapeutics compare to Maze Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AGMB vs. The Competition

AgomAb Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

AgomAb Therapeutics (AGMB) Competitors

AGMB vs. TRLV, HROW, TSHA, CMPS, and MAZE

How does AgomAb Therapeutics compare to Trulieve Cannabis?

Do analysts recommend TRLV or AGMB?

Is TRLV or AGMB more profitable?

Which has preferable valuation & earnings, TRLV or AGMB?

Does the media prefer TRLV or AGMB?

Summary

How does AgomAb Therapeutics compare to Harrow?

Which has stronger valuation and earnings, HROW or AGMB?

Do analysts prefer HROW or AGMB?

Do insiders & institutionals believe in HROW or AGMB?

Is HROW or AGMB more profitable?

Does the media refer more to HROW or AGMB?

Summary

How does AgomAb Therapeutics compare to Taysha Gene Therapies?

Which has stronger earnings and valuation, AGMB or TSHA?

Do insiders & institutionals hold more shares of AGMB or TSHA?

Do analysts rate AGMB or TSHA?

Is AGMB or TSHA more profitable?

Does the media prefer AGMB or TSHA?

Summary

How does AgomAb Therapeutics compare to Compass Pathways?

Which has preferable valuation & earnings, AGMB or CMPS?

Is AGMB or CMPS more profitable?

Do insiders & institutionals have more ownership in AGMB or CMPS?

Do analysts prefer AGMB or CMPS?

Does the media prefer AGMB or CMPS?

Summary

How does AgomAb Therapeutics compare to Maze Therapeutics?

Do analysts recommend AGMB or MAZE?

Is AGMB or MAZE more profitable?

Does the media refer more to AGMB or MAZE?

Which has stronger earnings and valuation, AGMB or MAZE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AGMB vs. The Competition

AgomAb Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools